Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Has Consensus Price Target of $49.50

Posted by Francis Steltz on Oct 11th, 2026

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have received an average recommendation of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $49.50.

A number of research firms recently issued reports on STRO. Mizuho raised Sutro Biopharma to a “strong-buy” rating in a report on Wednesday, September 16th. Stifel Nicolaus set a $48.00 price objective on Sutro Biopharma and gave the company a “buy” rating in a report on Friday, August 7th. Citizens Jmp cut their target price on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a report on Thursday, August 13th. Wells Fargo & Company began coverage on Sutro Biopharma in a research report on Wednesday, September 30th. They set an “overweight” rating and a $49.00 price target on the stock. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Sutro Biopharma in a research report on Thursday, August 13th.

Check Out Our Latest Analysis on Sutro Biopharma

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $14.27 on Friday. The firm has a market capitalization of $236.60 million, a P/E ratio of -1.19 and a beta of 1.49. The stock has a fifty day moving average price of $19.20 and a two-hundred day moving average price of $25.69. Sutro Biopharma has a 52-week low of $7.15 and a 52-week high of $43.85.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The company had revenue of $9.84 million for the quarter, compared to analysts’ expectations of $11.96 million. On average, equities research analysts predict that Sutro Biopharma will post -8.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds have recently modified their holdings of the stock. Orbimed Advisors LLC bought a new position in shares of Sutro Biopharma in the first quarter valued at about $19,956,000. Perceptive Advisors LLC acquired a new stake in Sutro Biopharma during the first quarter worth approximately $17,818,000. ADAR1 Capital Management LLC grew its holdings in shares of Sutro Biopharma by 681.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock worth $13,064,000 after purchasing an additional 457,364 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after buying an additional 321,137 shares during the period. Finally, Merck & Co. Inc. bought a new position in Sutro Biopharma in the second quarter valued at approximately $9,042,053. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

(Get Free Report)

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary cell-free protein synthesis and protein-engineering platforms to design and manufacture complex biologic medicines, including antibody-drug conjugates (ADCs) and immuno-oncology treatments.

Sutro’s principal product candidate is luveltamab tazevibulin, also known as luvelta or STRO-002, an ADC designed to target folate receptor alpha, a protein expressed in several cancers.